UFP Technologies, Inc. - Common Stock (UFPT)

UFP Technologies (NASDAQ:UFPT) reported third-quarter 2026 sales growth of 11.6%, supported by broad demand across its medical technology portfolio, while management outlined continued investments in capacity, operational improvements and acquisitions heading into 2027. Third-quarter sales totaled

What happened? A number of stocks jumped in the afternoon session after election results confirmed that Democrats reclaimed majorities in the House and Senat...

Margin gains and a shifting robotic surgery outlook shape the quarter.

Medical products company UFP Technologies (NASDAQ:UFPT) beat Wall Street’s revenue expectations in Q3 2026, with sales up 11.6% year on year to $172.4 millio...

Medical products company UFP Technologies (NASDAQ:UFPT) reported revenue ahead of Wall Street’s expectations in Q3 2026, with revenue rising 11.6% year on ye...

Medical products company UFP Technologies (NASDAQ:UFPT) will be announcing earnings results this Tuesday after market close. Here’s what to expect. UFP Techn...

The past six months have been a windfall for UFP Technologies’s shareholders. The company’s stock price has jumped 41.9%, hitting $289.13 per share. This was...

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how drug development input...

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size ...

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc...

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the drug development inputs & services industry, including Azenta...

Feldmann reduced her direct stake by 18%.

UFP Technologies (NASDAQ:UFPT) outlined its strategy to expand through organic growth and acquisitions, emphasizing its role as a contract development and manufacturing organization serving medical-device companies. President and Chief Executive Officer Mitch Rock said the company provides engineer

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...

Record $2.92 adjusted EPS and 15.1% net sales growth highlight strong MedTech momentum.

UFP Technologies delivered a calendar second quarter marked by strong, broad-based growth across its MedTech platform, which exceeded Wall Street’s revenue a...

UFP Technologies easily surpassed Wall Street's expectations and continued to deliver double-digit sales growth.

UFP Technologies (NASDAQ:UFPT) reported second-quarter 2026 sales growth of 15.1% to $174 million, supported by broad-based demand across its medical technology portfolio, while adjusted earnings per share rose 16.8% to a company-record $2.92. President and Chief Executive Officer Mitch Rock, speak

What Happened? Shares of medical products company UFP Technologies (NASDAQ:UFPT) jumped 18.5% in the morning session after the company reported impressive se...

UFP Technologies (NASDAQ:UFPT) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to our

Medical products company UFP Technologies (NASDAQ:UFPT) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 15.1% year on y...

Medical products company UFP Technologies (NASDAQ:UFPT) will be reporting results this Monday after market hours. Here’s what you need to know. UFP Technolog...

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...

As small caps outpace the S&P 500 in 2026's rotation, UFP Technologies, Willdan Group, and NWPX Infrastructure show earnings and growth catalysts worth watching this year.